DHR vs JPM: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and JPMorgan Chase & Co. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
VS
JPMorgan Chase & Co. · Financial Services
$325.22
+45.0% upside to fair value
Grade A
High Quality
QuantHub Verdict
JPM has more upside to fair value
(+45.0%).
JPM trades at a lower forward P/E
(15.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
JPM |
| Current Price |
$177.17 |
$325.22 |
| Fair Value Estimate |
$192.90 |
$471.57 |
| Upside to Fair Value |
+8.9%
|
+45.0%
|
| Market Cap |
$125.4B |
$871.4B |
| Forward P/E |
34.1x
|
15.6x
|
| EV / EBITDA |
20.8x
|
21.4x
|
| Price / Sales |
5.1x
|
3.1x
|
| Price / FCF |
23.7x
|
6.2x
|
| Revenue Growth YoY |
+3.7%
|
+6.9%
|
| Gross Margin |
60.7%
|
60.9%
|
| Operating Margin |
21.0%
|
26.2%
|
| Return on Equity |
7.1%
|
16.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.22%
|
16.18%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
JPMorgan Chase & Co. is a leading global financial services firm with a diversified banking franchise spanning consumer, corporate, commercial, and asset management segments. The company benefits from a durable competitive moat supported by a long-tenured CEO, strong management continuity, and leading market shares in key banking sectors. Its financial metrics show solid profitability with a retu…
Accumulation Zones
| Metric |
DHR |
JPM |
| Zone Low |
$144.68 |
$353.68 |
| Zone High |
$163.97 |
$400.83 |
| In Buy Zone? |
No
|
Yes
|